Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vaginal capsule wipe out persistent HPV?

NCT ID NCT07601074

Not yet recruiting Disease control Sponsor: Daré Bioscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 6 times

Summary

This study tests whether DARE-HPV, a vaginal capsule containing HIV drugs lopinavir and ritonavir, can clear persistent high-risk HPV infections in women aged 22-50. Participants will receive one of two doses for 14 or 21 days, or a placebo. The main goal is to see if the infection is gone 3 months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lopinavir/ritonavir vaginal capsule
What this could lead to
If successful, this could offer a non-surgical treatment option to clear persistent high-risk HPV infections, potentially reducing cervical cancer risk.
What could go wrong
This is an early Phase 2a trial with only 118 participants, so results may not confirm effectiveness. The drug is repurposed from HIV treatment, and its safety and efficacy for HPV are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK HUMAN PAPILLOMAVIRUS GENITAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anogenital human papillomavirus infection human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION HUMAN PAPILLOMA VIRUS (HPV)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Applied Research Center of Arkansas/Cornerstone Clinic for Women

    Little Rock, Arkansas, 72205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Precision Clinical Trials-Arizona

    Phoenix, Arizona, 85032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Seattle Clinical Research Center

    Seattle, Washington, 98104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.